Subscribe To
AVTE / Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market
AVTE News
By Seeking Alpha
April 12, 2023
Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market
AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient more_horizontal
By Seeking Alpha
January 29, 2023
Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy
Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 o more_horizontal